comparemela.com

Latest Breaking News On - Indoles - Page 1 : comparemela.com

MyJournals org - Science - [ASAP] Heterogeneous Photocatalytic C–H Functionalization of Indoles with Diazo Compounds Enabled by Carbon Nitride (Journal of Organic Chemistry)

MyJournals.org - Science - [ASAP] Heterogeneous Photocatalytic C–H Functionalization of Indoles with Diazo Compounds Enabled by Carbon Nitride (Journal of Organic Chemistry)

Phytonutrients: Natural compounds in plant foods that help lower cancer risk

Inhibitors of bacterial RNA polymerase transcription complex by Daniel S Wenholz, Michael Miller et al

A series of hybrid compounds that incorporated anthranilic acid with activated 1H-indoles through a glyoxylamide linker were designed to target bacterial RNA polymerase holoenzyme formation using computational docking. Synthesis, in vitro transcription inhibition assays, and biological testing of the hybrids identified a range of potent anti-transcription inhibitors with activity against a range of pathogenic bacteria with MICs as low as 3.1 μM. A structure activity relationship study identified the key structural components necessary for inhibition of both bacterial growth and transcription. Correlation of in vitro transcription inhibition activity with in vivo mechanism of action was established using fluorescence microscopy and resistance passaging using Gram-positive bacteria showed no resistance development over 30 days. Furthermore, no toxicity was observed from the compounds in a wax moth larvae model, establishing a platform for the development of a series of new antibacterial

Cadila Healthcare gets USFDA nod for lung cancer drug

Read more about Cadila Healthcare gets USFDA nod for lung cancer drug on Business Standard. The drug major has received tentative approval from the US drug regulator to market osimertinib tablets in the strengths of 40 mg and 80 mg.

AstraZeneca Pharma India gets DCGI approval for osimertinib tablets

AstraZeneca Pharma India has received import and market permission in Form CT-20 (subsequent New Drug Approval) from the Drugs Controller General of India for osimertinib 40mg/80mg film coated tablets (Tagrisso).Osimertinib 40mg/80mg film coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. The receipt of this permission paves way for the launch of osimertinib 40mg/80mg film coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses, the company said in a statement.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.